Accumulating evidence suggests that resistance to PD‐1 inhibitors is associated with factors such as the immunosuppressive state of the tumor microenvironment [13, 14, 15, 16], inadequate secretion of type I interferons [17, 18], insufficient expression of CRT on tumor cell surfaces [19], and low tumor immunogenicity [10, 20, 21]. The gene discussed is CALR; the disease is neoplasm.